What P.G. 600 Treats: Main Uses and Benefits

The therapeutic focus of P.G. 600 is strictly centered on managing the swine reproductive cycle to support overall breeding efficiency. This medication is used as a management tool to promote reproductive efficiency in swine operations.

---

Inducing a Cycle in Non-Cycling Swine

This use is applied in addressing the symptom of anestrus, or the functional absence of a fertile heat, which is relevant in specific animal groups. The medication is commonly used to initiate the first fertile cycle in prepuberal gilts and is applied in situations where weaned sows are experiencing a delayed return to estrus (Post-Weaning Anestrus). This treatment supports the establishment of a reproductive cycle, which helps with managing symptoms linked to organ-specific functional stress.

Standardizing Breeding Timelines and Efficiency

Beyond managing non-cycling states, P.G. 600 is applied across domains where additional symptomatic support is needed by facilitating the synchronization and standardization of the estrous cycle across groups of female swine. This application generally helps with predictable timing of breeding and may assist with group synchronization and batch farrowing. This ultimately assists with maintaining functional stability in the production flow, contributing to easing the overall symptom load by reducing non-productive days (NPSDs).

Quick Fact: Symptom Support
P.G. 600 is commonly used to help with conditions involving the functional absence of heat (anestrus) in weaned sows and the delayed onset of puberty in gilts.

Regulatory References

1. FDA product documentation

P.G. 600 is a veterinary medicinal product and its use is strictly confined to swine (gilts and sows) under specific physiological conditions, as defined by official regulatory labeling. Use in any other species is not indicated.

---

Eligibility Scope

Category	Regulatory Status
Populations Allowed	Healthy prepuberal (non-cycling) gilts and healthy weaned sows experiencing delayed return to estrus.
Contraindicated Use	Animals with known hypersensitivity to the active substances, or any component of the medicine.
Ineffective Use	Treatment will not induce estrus in animals that are already cycling normally or are currently pregnant.

---

Eligibility-Related Restrictions

• Maturity Requirements: Gilts must meet minimum physiological maturity standards, specified as being over five and one-half months of age and weighing at least 85 kg (187 lb.). Use in gilts below these thresholds is restricted.
• Reproductive State: The product is not indicated for use during pregnancy, as it will fail to produce heat and will not cause abortion.
• Normal Cyclers: The medicine is ineffective in gilts that have already reached puberty and in sows returning to estrus normally within three to seven days after weaning. The effectiveness of P.G. 600 has also not been established after later litters for delayed return to estrus.

Interactions with other medicines and products

Official regulatory documents, such as those published by the UK Veterinary Medicines Directorate (VMD) and the U.S. Food and Drug Administration (FDA) for this veterinary medicinal product, define the interaction profile of P.G. 600 (Serum Gonadotropin and Chorionic Gonadotropin) based on its known systemic effects and pharmaceutical characteristics.

Systemic Drug-Drug Interaction Profile

The regulatory label for P.G. 600 explicitly states that no interactions are known with other medicinal products. This classification formally indicates that there are no documented systemic pharmacokinetic interactions—such as those involving metabolic enzymes or drug transporters—and no documented pharmacodynamic interactions with other veterinary drugs.

Furthermore, no specific interactions with food, supplements, or herbal products are documented in the official regulatory prescribing information for this product.

Interaction-Related Restrictions

The only constraint noted in the official documentation that relates to product interaction is a mandatory procedural restriction concerning reconstitution. The freeze-dried powder component of P.G. 600 must be mixed only with the solvent supplied in the kit and must not be combined with any other veterinary medicinal product. This rule is a statement of physical and chemical incompatibility during preparation.

P.G. 600 is a combination synthetic gonadotropin, targeting ovarian cellular receptors. It contains Pregnant Mare Serum Gonadotropin (PMSG) and Human Chorionic Gonadotropin (hCG). PMSG is a functional agonist at the Follicle-Stimulating Hormone (FSH) receptor and, to a lesser extent, the Luteinizing Hormone (LH) receptor, primarily located on ovarian follicular cells. This interaction initiates the molecular and intracellular pathway of follicular growth and maturation.

Concurrently, hCG functions as a potent agonist at the LH receptor. The binding of hCG to the LH receptor on the mature follicular cells triggers the intracellular signaling cascade necessary for the terminal stage of follicular development and subsequent ovulation. The LH-like activity of hCG also promotes the cellular differentiation of the ovulated follicle into the corpus luteum. The downstream cascade involves the cellular synthesis and secretion of steroid hormones, primarily estrogen and progesterone, from the developing follicles and the corpus luteum, respectively. This systemic hormonal modulation facilitates the physiological preparation for the reproductive cycle.

How to Use P.G. 600

The usage of P.G. 600 involves a single, scheduled intervention to facilitate reproductive cycles in swine, requiring specific administration techniques and timing. This is not a chronic medication or one intended for repeated, daily use.

---

Administration Details

Instruction	Detail
Administration Route	The medicine is administered as an injection, used for either subcutaneous (SC) or intramuscular (IM) administration.
Dosing Schedule	A single 5 mL dose of the reconstituted solution is used for all indications. This dose delivers 400 IU Serum Gonadotropin and 200 IU Chorionic Gonadotropin.
Preparation	The product, supplied as a powder and solvent, requires reconstitution immediately prior to use. The prepared solution must be administered promptly.
Injection Site	The injection is specifically directed to the neck behind the ear.

---

Timing and Constraints

The timing of P.G. 600 administration is constrained by the animal's reproductive status and physical condition:

• Gilts must meet specific population criteria, requiring them to be over five and one-half months of age and weigh at least 85 kg (187 lb.) to be eligible for treatment.
• Sows receive the single dose either on the day of weaning or within 48 hours post-weaning to promote early estrus. In cases of delayed estrus, the injection may be given 8 to 12 days post-weaning.
• If a sow or gilt does not respond to the initial treatment, the injection may be repeated after a waiting period of 10 days.

These constraints ensure the standardized delivery of the medication is aligned with critical physiological windows.

Research Evidence / Overview of Studies for P.G. 600

Evidence for Use in Prepuberal Gilts and Weaned Sows

The research evidence for P.G. 600 is based on pivotal clinical studies and Randomized Controlled Trials (RCTs) submitted for regulatory review. These controlled, comparative studies examined the medicine's use in two primary populations.

For prepuberal gilts, the research explored the induction of the first fertile estrus in young, non-cycling animals meeting specific age and weight criteria. Studies tracked short-term outcomes such as the rate of estrus display and the time interval to onset of heat, along with subsequent farrowing success.

For weaned sows experiencing a delayed return to heat (Post-Weaning Anestrus), trials evaluated metrics like the Weaning-to-Estrus Interval (WEI) and the estrus response rate. Studies reported observations of an estrus response rate and WEI in the treated groups that differed from untreated control groups.

Consistency and Research Gaps

The evidence level for short-term outcomes (estrus timing and response) reflects a High classification in regulatory evaluations, describing the consistency of the study design. However, the evidence level for long-term production variables (e.g., subsequent litter size) is frequently assigned a Moderate classification due to variability in findings across different research settings.

A key research limitation is that long-term effects are not fully established regarding sustained productivity across the animal's entire reproductive life. Data for certain groups, such as animals outside the specific age and weight criteria or those with coexisting conditions, remains insufficient, meaning results apply only to the populations studied in the primary trials.

Common questions about P.G. 600 (FAQ)

---

Q: Is P.G. 600 the same as other medicines used for similar conditions?

P.G. 600 is a combination medicinal product with a specific composition. Official documents state it contains Serum Gonadotropin and Chorionic Gonadotropin, which are protein hormones that mimic the activity of natural FSH and LH to achieve its reproductive effect. While other products may address reproductive management, its combination of active ingredients and dual-hormone mechanism are specific to this formulation.

---

Q: Is alcohol consumption restricted when P.G. 600 is being used?

According to the official product information, there are no specific restrictions documented regarding the consumption of alcohol, food, supplements, or herbal products while P.G. 600 is in use. Regulatory documents formally state that no interactions are known with other medicinal products.

---

Q: What should be done if P.G. 600 is accidentally administered to someone who should not receive it?

The regulatory warnings advise that care should be taken to avoid accidental self-injection during administration. If accidental self-injection occurs, the person should seek immediate medical advice. Regulatory guidance instructs that the person should show the product package leaflet or label to the physician upon seeking care.

---

Q: Does P.G. 600 interact with birth control pills?

Regulatory documents formally state that no interactions are known with other medicinal products. It is important to note that P.G. 600 is formally classified as a veterinary medicine strictly intended for animal use only, and its interaction profile is documented within that scope.

---

Q: Is P.G. 600 used in veterinary medicine?

Yes, P.G. 600 is officially classified as a specialized veterinary medicinal product. It is intended exclusively for use in swine, specifically gilts and sows, to facilitate and standardize the reproductive cycle.

---

Q: Can P.G. 600 be used in human medicine?

Official regulatory documentation is clear that P.G. 600 is a veterinary medicinal product. It is strictly intended and indicated for animal use only, according to the regulatory labels.

---

Q: Can P.G. 600 affect long-term fertility?

Studies and official information indicate that the research evidence regarding long-term production outcomes is generally assigned a Moderate classification due to variability in findings. Regulatory data indicates that long-term effects regarding sustained productivity across the animal's entire reproductive life are not fully established.

---

Q: What is the regulatory status of P.G. 600?

P.G. 600 is formally classified as a veterinary medicinal product by regulatory bodies. In some jurisdictions, the product is subject to prescription.

---

Q: Why is P.G. 600 sometimes administered multiple times?

P.G. 600 is typically a single scheduled intervention. However, the official documents permit the injection to be repeated after a waiting period of 10 days if the treated animal fails to respond to the initial treatment.

---

Q: Why is P.G. 600 not recommended for pregnant individuals?

Official regulatory documents explain that the product is not indicated for use during pregnancy. The documents further state that administration to a pregnant animal will fail to produce heat and will not cause abortion.

---

Q: Is P.G. 600 a generic or a branded medicine?

P.G. 600 is a branded veterinary medicine. It has a listed Marketing Authorisation Holder, which is standard for branded products.

---

Q: What are the official contraindications listed for P.G. 600?

The official regulatory documents list known hypersensitivity to the active substances—Serum Gonadotropin and Chorionic Gonadotropin—or any other component of the medicine as a contraindication for use.

Storage and Disposal Requirements for P.G. 600

The storage of P.G. 600 is strictly defined by regulatory documents to maintain the stability of the powder and solvent.

Storage Conditions

• Temperature and Light: The product, in both its unreconstituted and reconstituted forms, must be stored in a refrigerator at a temperature between 2°C and 8°C and must be protected from light.
• Stability: The unopened product has a shelf life of 3 years. The reconstituted solution is stable for only 24 hours when kept refrigerated, after which any unused portion must be discarded.
• Safety: The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Official regulations prohibit the disposal of P.G. 600 via wastewater or household waste. All unused product and waste materials must be disposed of in accordance with local requirements and national collection systems for veterinary medicinal products.